Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meetingBoris Jülg, Bruce D. Walker, Krista L. Dong et al.|The Lancet HIV|2019Cited by 206
Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markersPablo Tebas, Steven D. Douglas, Sergei Spitsin et al.|AIDS|2015Cited by 38
Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretroviralsMark Manak, Steven D. Douglas, Dmitry Moshkoff et al.|AIDS|2010Cited by 36
Neurokinin-1 Receptor Antagonist (Aprepitant) Inhibits Drug-Resistant HIV-1 Infection of Macrophages in vitroXu Wang, Wen‐Zhe Ho, Steven D. Douglas et al.|Journal of Neuroimmune Pharmacology|2007Cited by 36